Department of Research, Cancer Registry of Norway, Oslo, Norway.
Department of Biostatistics, Oslo Centre for Biostatistics and Epidemiology, University of Oslo, Oslo, Norway.
Cancer Med. 2021 Jun;10(12):4107-4116. doi: 10.1002/cam4.3960. Epub 2021 Jun 3.
High circulating levels of vitamin D (25(OH)D) are suggested to reduce the risk of urinary bladder cancer (BC), but the evidence is weak, and several studies lack sufficient adjustment for potential confounders (e.g., smoking, body mass index (BMI), and physical activity). Moreover, few studies have investigated the role of vitamin D-binding protein (DBP) in this context. We conducted a matched nested case-control study including 378 cases and 378 controls within the Norwegian population-based Janus cohort, using serum collected 5-41 years prior to diagnosis, to study 25(OH)D and BC risk, by taking circulating DBP into account.
Cox regression models were used to estimate hazard ratios (HRs) and 95% confidence intervals (CIs), for 25(OH)D, DBP, and the molar ratio of 25(OH)D:DBP, an estimate of unbound (free) 25(OH)D levels. We adjusted for smoking (status and pack-years), BMI, physical activity, education and (mutually) for 25(OH)D and DBP. Restricted cubic splines were employed to examine nonlinear associations.
High optimal levels of circulating 25(OH)D (≥100 nmol/L) (HR 0.35, 95% CI 0.19-0.64) were associated with decreased BC risk, when compared with insufficient concentrations (50-74 nmol/L). This association was less pronounced for optimal levels (75-99 nmol/L) (HR = 0.69, 95% CI 0.47-1.01). Moreover, estimated free 25(OH)D, was associated with decreased BC risk for molar ratio 17-21 (HR 0.66, 95% CI 0.44-0.97) and ≥22 (HR 0.50, 95% CI 0.29-0.82), compared to molar ratio 11-16. The HR function for BC risk was not linear, rather reversed u-shaped, with the highest HR at 62.5 nmol/L and 13.5 molar ratio, respectively.
High levels of total and estimated free 25(OH)D were associated with reduced risk of BC, compared with insufficient concentrations. DBP was not associated with BC risk. We did not observe any impact of DBP or any of the studied lifestyle factors on the association between 25(OH)D and BC.
高循环水平的维生素 D(25(OH)D)被认为可以降低膀胱癌(BC)的风险,但证据不足,并且一些研究对潜在混杂因素(如吸烟、体重指数(BMI)和体力活动)的调整不足。此外,很少有研究调查维生素 D 结合蛋白(DBP)在这方面的作用。我们进行了一项匹配的嵌套病例对照研究,包括挪威基于人群的扬努斯队列中的 378 例病例和 378 例对照,使用在诊断前 5-41 年采集的血清,以考虑循环 DBP 来研究 25(OH)D 与 BC 风险之间的关系。
Cox 回归模型用于估计 25(OH)D、DBP 和 25(OH)D:DBP 摩尔比(估计无结合(游离)25(OH)D 水平)的风险比(HR)和 95%置信区间(CI)。我们调整了吸烟状况(吸烟状况和吸烟年数)、BMI、体力活动、教育和(相互)25(OH)D 和 DBP。受限立方样条用于检查非线性关联。
与浓度不足(50-74nmol/L)相比,循环 25(OH)D 高最佳水平(≥100nmol/L)(HR0.35,95%CI0.19-0.64)与 BC 风险降低相关。对于最佳水平(75-99nmol/L)(HR=0.69,95%CI0.47-1.01),这种关联不太明显。此外,与摩尔比 11-16 相比,摩尔比 17-21(HR0.66,95%CI0.44-0.97)和≥22(HR0.50,95%CI0.29-0.82)的估计游离 25(OH)D 与 BC 风险降低相关。BC 风险的 HR 函数不是线性的,而是反向 U 形,最高 HR 分别为 62.5nmol/L 和 13.5 摩尔比。
与浓度不足相比,总 25(OH)D 和估计的游离 25(OH)D 水平较高与 BC 风险降低相关。DBP 与 BC 风险无关。我们没有观察到 DBP 或任何研究的生活方式因素对 25(OH)D 与 BC 之间关联的任何影响。